Kiniksa Pharmaceuticals, Ltd.
KNSANASDAQHealthcare● Active
$49.04
+$0.62(+1.28%)
Market Cap$3.7B
P/E Ratio—
52W High$59.87
52W Low$26.27
Kiniksa Pharmaceuticals, Ltd. (KNSA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KNSA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$0.27
Est. $0.18 · +50.0%
Revenue
$0.21B
Est. $0.21B · +4.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
KNSA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 28, 2026 | $0.30 | — | — | — | $0.23B | — |
| ▲ Q2 FY2026 | Apr 28, 2026 | $0.18 | $0.27 | +50.0% | $0.21B | $0.21B | +4.0% |
| ▼ Q1 FY2026 | Feb 24, 2026 | $0.29 | $0.17 | -41.4% | $0.20B | $0.20B | +0.7% |
| ▼ Q4 FY2025 | Oct 28, 2025 | $0.33 | $0.23 | -30.3% | $0.18B | $0.20B | -8.2% |
| ▲ Q3 FY2025 | Jul 29, 2025 | $0.18 | $0.23 | +27.8% | $0.16B | $0.17B | -5.8% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $0.02 | $0.11 | +450.0% | $0.14B | $0.13B | +4.5% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -$0.06 | -$0.12 | -100.0% | $0.12B | $0.12B | -0.7% |
| ▼ Q4 FY2024 | Oct 29, 2024 | -$0.02 | -$0.18 | -662.4% | $0.11B | $0.12B | -9.1% |
Q3 FY2026
Jul 28, 2026
EPS Actual
—
EPS Est.
$0.30
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Beat
EPS Actual
$0.27
EPS Est.
$0.18
EPS Surpr.
+50.0%
Revenue
$0.21B
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
$0.17
EPS Est.
$0.29
EPS Surpr.
-41.4%
Revenue
$0.20B
Q4 FY2025
Oct 28, 2025Miss
EPS Actual
$0.23
EPS Est.
$0.33
EPS Surpr.
-30.3%
Revenue
$0.18B
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
$0.23
EPS Est.
$0.18
EPS Surpr.
+27.8%
Revenue
$0.16B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$0.11
EPS Est.
$0.02
EPS Surpr.
+450.0%
Revenue
$0.14B
Q1 FY2025
Feb 25, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.06
EPS Surpr.
-100.0%
Revenue
$0.12B
Q4 FY2024
Oct 29, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.02
EPS Surpr.
-662.4%
Revenue
$0.11B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.45 | $0.46 | $0.47 | 1 |
| Q3 FY2027 | $0.41 | $0.42 | $0.43 | 1 |
| Q2 FY2027 | $0.38 | $0.39 | $0.40 | 1 |
| Q1 FY2027 | $0.34 | $0.35 | $0.36 | 1 |
| Q4 FY2026 | $0.38 | $0.39 | $0.39 | 1 |
| Q3 FY2026 | $0.34 | $0.36 | $0.38 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q2 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q1 FY2027 | $0.3B | $0.3B | $0.3B | 2 |
| Q4 FY2026 | $0.3B | $0.3B | $0.3B | 2 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 28, 2026 | +50.0% | $43.61 | $53.85 | +23.48% |
| ▼ Q1 FY2026 | Feb 24, 2026 | -41.4% | $47.39 | $43.50 | -8.21% |
| ▼ Q4 FY2025 | Oct 28, 2025 | -30.3% | $40.60 | $39.43 | -2.88% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +27.8% | $27.04 | $30.37 | +12.32% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +450.0% | $21.47 | $25.88 | +20.54% |
| ▼ Q1 FY2025 | Feb 25, 2025 | -100.0% | $19.63 | $19.72 | +0.46% |
| ▼ Q4 FY2024 | Oct 29, 2024 | -662.4% | $27.59 | $23.27 | -15.66% |
| ▲ Q3 FY2024 | Jul 23, 2024 | +33.3% | $21.39 | $26.29 | +22.91% |
Q2 FY2026+23.48%
Report Date
Apr 28, 2026
EPS Beat/Miss
+50.0%
Price Before
$43.61
Price After
$53.85
Q1 FY2026-8.21%
Report Date
Feb 24, 2026
EPS Beat/Miss
-41.4%
Price Before
$47.39
Price After
$43.50
Q4 FY2025-2.88%
Report Date
Oct 28, 2025
EPS Beat/Miss
-30.3%
Price Before
$40.60
Price After
$39.43
Q3 FY2025+12.32%
Report Date
Jul 29, 2025
EPS Beat/Miss
+27.8%
Price Before
$27.04
Price After
$30.37
Q2 FY2025+20.54%
Report Date
Apr 29, 2025
EPS Beat/Miss
+450.0%
Price Before
$21.47
Price After
$25.88
Q1 FY2025+0.46%
Report Date
Feb 25, 2025
EPS Beat/Miss
-100.0%
Price Before
$19.63
Price After
$19.72
Q4 FY2024-15.66%
Report Date
Oct 29, 2024
EPS Beat/Miss
-662.4%
Price Before
$27.59
Price After
$23.27
Q3 FY2024+22.91%
Report Date
Jul 23, 2024
EPS Beat/Miss
+33.3%
Price Before
$21.39
Price After
$26.29
Avg Beat Reaction+19.81%
Avg Miss Reaction-6.57%
Beat Rate4 / 8 quarters
Largest Move+23.48% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KNSA ends December
Kiniksa Pharmaceuticals, Ltd. (KNSA) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $0.27 — beating the analyst consensus of $0.18 by +50.0%. The next KNSA earnings date is expected around September 1, 2026.
Each quarter, investors track KNSA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KNSA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KNSA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KNSA earnings · 5 questionsKiniksa Pharmaceuticals, Ltd.'s next earnings report is expected around September 1, 2026. KNSA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KNSA historically reports after market close (AMC).
KNSA earnings datewhen is KNSA earningsKNSA next earnings datewhen does KNSA report earningsKNSA earnings calendar
▸ Source: FMP · Kiniksa Pharmaceuticals, Ltd. SEC filings · US GAAP · Kiniksa Pharmaceuticals, Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026